Prostatype gives you a more accurate answer
Determining the prognosis for prostate cancer is like trying to put a puzzle together without all the pieces. Experienced doctors can get very far when it comes to giving the right diagnosis and prognosis, but in many cases it is difficult to determine with certainty how dangerous a cancer is and which possible treatments are best.
Oftentimes treatment is not necessary at all, and it’s sufficient with regular healthcare visits/check ups to ensure the cancer hasn’t developed in a way that would make treatment necessary. Some patients are unnecessarily operated, and in a number of cases aggressive prostate cancer which should be treated is missed.
Prostatype gives new prerequisites for reaching a clearer answer. Through gene analysis, the patient and doctor receive a measure indicating how aggressive or non-aggressive the cancer is. It provides a better basis when faced with the often difficult treatment decision.
Prostatype provides the patient and doctor with supplementary information prior to making a decision on whether or not treatment is necessary.
Prostatype’s unique system takes the cancer’s genetic fingerprint by measuring information from cancer stem cell genes in the tissue sample (the biopsy) which has already been taken in connection with the diagnosis. This is combined with other information from the diagnosis (PSA test, Gleason score, etc.), and a so called P-score is calculated. A P-score provides a measure of how aggressive or non-aggressive the cancer is, which eases the choice of optimal treatment.
The result is an important piece of the puzzle and a valuable basis for doctor and patient in the conversation on how to proceed.
Development of Prostatype started in 2007 by a research group from The Karolinska Institute. The test is supplied by Chundsell Medicals AB.
Prostatype is available for patients and treating urologists as a supplementary decision basis in the question of whether or not to treat prostate cancer.
It is not necessary to carry out a new biopsy as the existing sample, which was taken to diagnose prostate cancer, can be used.
As a treating urologist, you can easily order Prostatype.
Download the order form below.
Test Requisition Form (pdf)
Completed forms can also be mailed to email@example.com
Read more about ordering Prostatype here: prostatype.dev.dazy.se/urologer
The Prostatype test system is delivered in a kit format (adapted to qPCR platform LightCycler480 I and II) and can be performed in most laboratories. The test can also be carried out at Chundsell Medicals’ IVO certified laboratory in Stockholm. Prostatype is CE marked. All production of Prostatype is done in accordance with the GMP standard. Chundsell Medicals is ISO certified according to the ISO 13485 standard.
Prostatype has been validated clinically and in several studies, conducted and ongoing. Prostatype has been shown to improve the ability to predict survival and the best choice of treatment method for individual patients through the analysis of patients’ genes, which is compared with data from similar patient cases in the Chundsell Medicals CPMA database.
Links to studies and more:
Improving the Prediction of Prostate Cancer Overall Survival by Supplementing Readily Available Clinical Data with Gene Expression Levels of IGFBP3 and F3 in Formalin-Fixed Paraffin Embedded Core Needle Biopsy Material.
Validation of a 3-gene Signature and Development of an Authentic Cohort Database to Improve Overall Survival Prediction and Clinical Treatment Decision for Patients With Newly Diagnosed Prostate Cancer.
Read more about Prostatype at Chundsell.com